Company news

Nuwellis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®

September 30, 2025

Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration

September 18, 2025

Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment

September 17, 2025

Nuwellis’ Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio

September 9, 2025

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

September 4, 2025

Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter

August 21, 2025

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company

August 19, 2025

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 15, 2025

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

August 14, 2025

Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

August 7, 2025

Nuwellis Postpones Second Quarter 2025 Earnings Release and Conference Call to August 14, 2025

August 6, 2025

Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code

August 5, 2025

Nuwellis Stockholders Approve All Proposals at Special Meeting

August 4, 2025

Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 23, 2025

Nuwellis Regains Compliance with Nasdaq Listing Requirements

July 23, 2025

Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025

July 22, 2025

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

July 17, 2025

Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation

July 15, 2025

Nuwellis Appoints John Erb as Chief Executive Officer

July 2, 2025

Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

June 10, 2025

Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering

June 9, 2025

Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

May 13, 2025

Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency

May 11, 2025

Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

May 8, 2025

Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision

April 24, 2025

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

April 22, 2025

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

March 11, 2025

Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

February 24, 2025

JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis

February 20, 2025

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

February 18, 2025

Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow® Therapy

January 12, 2025

Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights

November 10, 2024

Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

November 4, 2024

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

November 3, 2024

Nuwellis Announces Preliminary Results for Third Quarter of 2024

October 31, 2024

Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer

October 30, 2024

Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

October 22, 2024

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

August 22, 2024

Nuwellis, Inc. Announces Second Quarter 2024 Financial Results

August 12, 2024

Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s

July 25, 2024

Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules

July 23, 2024

Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s

July 16, 2024

Nuwellis Announces Reverse Stock Split

June 25, 2024

Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™

June 24, 2024

Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase

June 5, 2024

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida

May 13, 2024

Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy

May 8, 2024

Nuwellis, Inc. Announces First Quarter 2024 Financial Results

May 6, 2024

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

May 1, 2024

Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024

April 29, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 26 decks. Every deck is listed under its year.